Best Michael Underscore Podcasts (2025)

1
S13 Ep19: Long-Term Data Underscore the Enduring Efficacy of PD-1 Inhibition in Nasopharyngeal Carcinoma: With Michael Dennis, MD 15:55

Play Pause

3d ago15:55

15:55

In today’s episode, supported by Coherus BioSciences, we had the pleasure of speaking with Michael Dennis, MD, about recent updates to the nasopharyngeal carcinoma treatment paradigm. Dr Dennis is a physician at Dana-Farber Cancer Institute; as well as an instructor in medicine at Harvard Medical School, both in Boston, Massachusetts. In our exclus…

1
S13 Ep22: BRAF-Mutant and HER2+ mCRC Management Strategies Are Becoming Increasingly Tailored: With Chandler Park, MD, and Midhun Malla, MD 9:27

1h ago9:27

9:27

In this episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Midhun Malla, MD, a gastrointestinal oncologist at Allegheny Health Network in Pittsburgh, Pennsylvania, to discuss treatment personalization in metastatic colorectal cancer (mCRC), w…

1
S13 Ep21: T-DXd's Efficacy Stands Strong and Supports IHC Testing in HER2-Mutated NSCLC: With Misako Nagasaka, MD, PhD 6:18

14h ago6:18

6:18

In today’s episode, supported by Daiichi Sankyo, we had the pleasure of speaking with Misako Nagasaka, MD, PhD, about the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in pretreated patients with HER2-mutated non–small cell lung cancer (NSCLC). Dr Nagasaka is an associate professor in the Division of Hematology and Oncology and the Divisi…

1
S13 Ep20: ASCO 2025 Plenary: SERENA-6 12:33

2d ago12:33

12:33

In this episode, OncLive On Air® partnered with Two Onc Docs to bring discussion of data from the phase 3 SERENA-6 trial (NCT04964934), which were presented at the 2025 ASCO Annual Meeting. SERENA-6 evaluated switching to camizestrant plus a CDK4/6 inhibitor vs continuing with a standard-of-care aromatase inhibitor plus a CDK4/6 inhibitor in the fr…

1
S13 Ep18: Conversations About BTK Inhibitors and CAR T-Cell Therapies Bridge Gaps in Leukemia and Lymphoma: With Alexey Danilov, MD, PhD 19:58

7d ago19:58

19:58

In today’s episode, we had the pleasure of speaking with Alexey Danilov, MD, PhD, about current challenges and emerging treatment approaches for the management of leukemia and lymphoma that were published in a manuscript based on proceedings from the inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Dr Danilov is t…

1
S13 Ep17: 42nd Annual Miami Breast Cancer Conference® Podcast: OncLive On Air CE, Powered by PER 26:40

8d ago26:40

26:40

Episode Description In this podcast, expert Hope Rugo, MD, discusses her approach to treating patients with hormone receptor–positive/HER2-negative breast cancer from the early-stage to metastatic disease. Consideration of these complex clinical scenarios taken from tumor board discussions at the 42nd Annual Miami Breast Cancer Conference® highligh…

1
S13 Ep16: Liquid Imatinib Formulation Expands Leukemia Treatment Options and Improves Treatment Adherence: With Kate Gasparini, PharmD, BCOP, BCPPS 11:10

8d ago11:10

11:10

In today’s episode, supported by Shorla Oncology, we had the pleasure of speaking with Kate Gasparini, PharmD, BCOP, BCPPS, about the use of the oral formulation of imatinib (Imkeldi) for pediatric and adult patients with select leukemias and other malignancies. Gasparini is a pediatric oncology clinical pharmacy specialist at Memorial Sloan Ketter…

1
S13 Ep15: The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH 11:25

10d ago11:25

11:25

In our exclusive interview, Dr Morgans detailed the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide (Nubeqa) for this population. She discussed treatment considerations for determining whether to give docetaxel along with darolutamide; other factors to remember with AR inhibition; and the…

1
S13 Ep14: Revumenib Shows Promise Across Menin-Sensitive AML Subtypes and Could Shift Treatment Paradigms: With Naval Daver, MD 11:04

14d ago11:04

11:04

In today’s episode, we spoke with Naval Daver, MD, about the evolving role of menin inhibition in acute myeloid leukemia (AML) and emerging data with revumenib (Revuforj) presented across ongoing clinical trials. Dr Daver is a professor in the Department of Leukemia and director of the Leukemia Research Alliance Program at The University of Texas M…

1
S13 Ep13: T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD 14:41

15d ago14:41

14:41

In today’s episode, we spoke with Paolo Tarantino, MD, about key updates in HER2-positive breast cancer presented at the 2025 ASCO Annual MeetingBy OncLive® On Air

1
S13 Ep12: Telisotuzumab Vedotin Shakes Up Management of Pretreated, c-MET–Overexpressing NSCLC: With Jonathan W. Goldman, MD 9:26

16d ago9:26

9:26

In today's episode, we spoke with Jonathan W. Goldman, MD, about the phase 2 LUMINOSITY study (NCT03539536) evaluating telisotuzumab vedotin-tllv (Teliso-V; Emrelis) in patients with c-MET protein–overexpressing, nonsquamous, EGFR wild-type advanced non–small cell lung cancer (NSCLC). Dr Goldman is a professor of medicine in the Division of Hematol…

1
S13 Ep11: Collaborative Structural Reforms Represent a Way Forward for Oncology Innovations: With Elizabeth Mittendorf, MD, PhD, MHCM 9:48

17d ago9:48

9:48

In today’s episode, we sat down for part 2 of our discussion with Elizabeth Mittendorf, MD, PhD, MHCM, the 2026-2027 president-elect of the American Society of Clinical Oncology (ASCO). Dr Mittendorf holds numerous leadership roles, including the Robert and Karen Hale Distinguished Chair in Surgical Oncology and vice chair for research in the Depar…

1
Time Pals Summer Rewind 48:57

20d ago48:57

48:57

This week, the Time Pals celebrate our first year as a geek dad team—just in time for our month-long summer break (and, regrettably, to give Underscore a reprieve from producing our unique brand of chaos). From questions born of an ADHD mind, to AI-generated improv adventure stories, cruelly forgotten movie and video game gems, and an array of awes…

1
S13 Ep10: Updates and Innovations in Non-Opioid Pain Management Strategies for Breast Cancer Patients Post-Surgical Intervention 1:32:30

22d ago1:32:30

1:32:30

This PER® featured podcast includes a discussion with 3 experts on best practices for integrating opioid-sparing strategies into the treatment paradigm along with updates including the 2025 NOPAIN Act. The panel includes members of the care team including the surgical oncologist and anesthesiologist. This program is designed to help clinicians reco…

1
S13 Ep9: Multidisciplinary Collaboration and Mentorship Lay the Foundation for a New Chapter of ASCO Leadership: With Elizabeth Mittendorf, MD, PhD, MHCM 12:53

24d ago12:53

12:53

In today’s episode, we had the pleasure of speaking with Elizabeth Mittendorf, MD, PhD, MHCM, the 2026 president-elect of ASCO. Dr Mittendorf is the Robert and Karen Hale Distinguished Chair in Surgical Oncology and the vice chair for research in the Department of Surgery at the Brigham and Women's Hospital; co-leader of the Breast Program and dire…

1
S13 Ep8: Oncology PER® Spectives: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma 54:11

24d ago54:11

54:11

This Oncology PER®Spectives™ podcast examines the recent advancements in the treatment landscape for advanced melanoma. In this activity, experts Yana Najjar, MD; Rahul A. Sheth, MD, FSIR; and Douglas Johnson, MD, MSCI, discuss the challenges of immune checkpoint inhibitor resistance and the practical strategies for overcoming this by using direct …

1
S13 Ep7: Evolving Molecular Profiling and Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: With Chandler Park, MD; and Midhun Malla, MD 9:09

28d ago9:09

9:09

Drs Park and Malla began by talking through the clinical utility of ctDNA in patients with stage II and III colon cancer. Dr Malla referenced the DYNAMIC (ACTRN12615000381583) and observational BESPOKE CRC (NCT04264702) trials, noting that ctDNA serves as a prognostic biomarker for recurrence and is increasingly used to guide post-surgical surveill…

1
S13 Ep6: FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD 7:48

29d ago7:48

7:48

In today’s episode, we spoke with Matthew Galsky, MD, about the FDA approval of neoadjuvant durvalumab (Imfinzi) plus gemcitabine and cisplatin followed by adjuvant durvalumab monotherapy after radical cystectomy for the treatment of adult patients with muscle-invasive bladder cancer (MIBC). Dr Galsky is a professor of medicine (hematology and medi…

1
S13 Ep5: Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD 8:56

1M ago8:56

8:56

In this week’s episode of MedNews Week’s Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Paul Hanona, MD, to give advice to up-and-coming oncology content creators. Dr Hanona is a content creator under the handle @doctordiscover. In the final part of this 3-part se…

1
S13 Ep4: Eltrombopag Biosimilar Improves Accessibility for Immune Thrombocytopenia & Aplastic Anemia: With Kanwarpal S. Kahlon, MD 8:24

1M ago8:24

8:24

In today’s episode, supported by Camber Pharmaceuticals, we spoke with Kanwarpal S. Kahlon, MD, an associate clinical professor of medicine at the UCLA School of Medicine. In our exclusive interview, Dr Kahlon discussed the significance of the commercial availability of the generic, AB-rated formulations of eltrombopag (Promacta), a bioequivalent m…

1
S13 Ep3: Updated Nilotinib Formulation Improves Treatment Adherence in Ph+ CML: With Michael J. Mauro, MD 12:59

1M ago12:59

12:59

In today’s episode, supported by Azurity Pharmaceuticals, we spoke with Michael J. Mauro, MD, about treatment adherence with nilotinib (Tasigna/Danziten) in patients with Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML). Dr Mauro is an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York. In our ex…

1
S13 Ep2: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer 49:30

1M ago49:30

49:30

This featured podcast includes a discussion with 3 experts on managing patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) from a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. In observational studies of treatment patterns in older women with …

1
Time Pals X Black Curtain Club Podcast: Saturday Morning Nightmares 56:51

1M ago56:51

56:51

This week, the Time Pals bring their flashlights and emotional support wine as they dig up the creepiest, weirdest, and most nightmare-inducing moments from the kids' shows we grew up with. Too scared to face it alone, hosts Mike Underscore and Jon Powell enlist their friends Angie and Becca from the Black Curtain Club Podcast to hold their hands a…

1
S13 Ep1: Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott 24:09

1M ago24:09

24:09

In today’s episode, we spoke with Shubham Pant, MD, MBBS, and Professor Timothy Elliott, about ongoing research with cancer vaccines. Dr Pant is a professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. Dr Elliott is the Kidani Professor of …

1
S12 Ep50: Optimizing Today and Looking to Tomorrow in Metastatic CRPC - Homing in on EZH2 43:33

1M ago43:33

43:33

This Oncology PER®Spectives™ podcast explores the role of EZH2 in metastatic castration-resistant prostate cancer (mCRPC) progression and its synergy with androgen receptor inhibitors. In this podcast, experts Neeraj Agarwal, MD, FASCO; Himisha Beltran, MD; and Maha Hussain, MD, FACP, FASCO, discuss the management of mCRPC. Acknowledgment of Educat…

1
S12 Ep49: MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD 12:54

1M ago12:54

12:54

In today’s episode, supported by SpringWorks Therapeutics, we spoke with Christopher L. Moertel, MD, about the evolution of treatments for neurofibromatosis type 1 (NF1)–associated plexiform neurofibromas (PN). Dr Moertel is a professor and the Pediatric Neuro-Oncology Fellowship Program director in the Division of Pediatric Hematology/Oncology, a …

1
S12 Ep48: Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation 1:17:00

2M ago1:17:00

1:17:00

This featured podcast includes a data review and candid conversation with 4 experts on challenges in the current treatment paradigm for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) due to endocrine resistance. This session occurred during a satellite symposium held in conjunction with the 42nd Annual Miami Brea…

1
S12 Ep47: Early-Phase RAS Inhibitor Research Sparks Interest in NSCLC: With Kathryn C. Arbour, MD 9:43

2M ago9:43

9:43

In today’s episode, supported by Revolution Medicines, we spoke with Kathryn C. Arbour, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, about 2 important abstracts presented at the 2024 AACR Annual Meeting that explore novel RAS-targeted approaches in non–small cell lung cancer (NSCLC). Our discuss…

1
S12 Ep46: Managing Side Effects and Fertility for Premenopausal Patients with Advanced HR+ Breast Cancer 1:04:27

2M ago1:04:27

1:04:27

This expert podcast includes an engaging discussion among 3 experts on fertility care of patients with breast cancer. This program is designed to help clinicians better recognize and take steps to discuss fertility options in premenopausal patients with hormone receptor-positive (HR+) breast cancer to facilitate care for those women who wish to pre…

1
S12 Ep45: RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA 10:56

2M ago10:56

10:56

In today’s episode, supported by Replimune, we had the pleasure of speaking with Anna C. Pavlick, BSN, MSc, DO, MBA, about the use of RP1 plus nivolumab (Opdivo) for the treatment of patients with advanced melanoma. Dr Pavlick is a professor of medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine in New York, New York…

1
A Time Pals Adventure 002: A Long Time Ago, in a Podcast Far, Far Away 51:45

2M ago51:45

51:45

The Time Pals celebrate Star Wars Day and the re-release of “Revenge of the Sith” by going on a dungeon adventure set in the Star Wars universe. This time your Pals attempt to break the artificial intelligence storyteller with a lightsaber to the gut and craft a completely original story that won’t at all resemble "The Book of Boba Fett" in meaning…

1
The Time Pals of Us (Feat. Britt McKay of "Something Offensive Podcast" 50:21

2M ago50:21

50:21

This week, the Time Pals get into a roundtable discussion and delve into Naughty Dog's acclaimed game, The Last of Us, and its recent adaptation into a television series. Joining us is author/writer, film school student, and host of the upcoming "Something Offensive Podcast", Britt McKay. Together, we explore the emotional impact of the game and th…

1
S12 Ep44: Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH 12:33

2M ago12:33

12:33

In today’s episode, we had the pleasure of speaking with Jacob Moyer, BS, and Mark Tyson II, MD, MPH, about a real-world study investigating nadofaragene firadenovec in patients with BCG-unresponsive NMIBC. Moyer is a graduate researcher at Mayo Clinic in Scottsdale, Arizona. Tyson is a urologic oncologist and an associate professor of urology at t…

1
S12 Ep43: Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD 19:32

2M ago19:32

19:32

In today’s episode, we had the pleasure of speaking with Nicole Lamanna, MD, about patient selection considerations for the use of pirtobrutinib (Jaypirca) in the management of chronic lymphocytic leukemia (CLL). Dr Lamanna is a hematologic oncologist at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irvi…

1
S12 Ep42: Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD 7:28

2M ago7:28

7:28

In today’s episode, we had the pleasure of speaking with Daniel P. Petrylak, MD, about Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in metastatic castration-resistant prostate cancer (mCRPC). Dr Petrylak is a professor of medicine (medical oncology) and urology, as well as the chief of Genitourinary Oncology, at Yale School of Medicine and Smil…

1
S12 Ep41: Oncodetect MRD Detection Aids Treatment Decision-Making in CRC and Other Solid Tumors: With Eric Christenson, MD 13:53

2M ago13:53

13:53

In today’s episode, supported by Exact Sciences, we had the pleasure of speaking with Eric Christenson, MD, about the Oncodetect test, which is available for use in molecular residual disease detection in patients with solid tumors. Dr Christenson is an assistant professor of oncology at the Johns Hopkins School of Medicine in Baltimore, Maryland. …

1
S12 Ep40: Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD 9:12

2M ago9:12

9:12

In this week’s episode of MedNews Week’s Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Paul Hanona, MD, to give advice to up-and-coming oncology content creators. Dr Hanona is the chief Hematology Oncology Fellow at Beaumont Health in Royal Oak, Michigan. He is a…

1
Time Pals FINISH the Oscars Worst (2010-2020 Wrap Up) 1:16:17

2M ago1:16:17

1:16:17

This week the Time Pals finally did it—We finished fixing the rest of the Academy’s gross mistakes—and for the surprisingly competitive decade of 2010 to 2020. We discuss the films that deservedly had a chance at greatness and remove the ones that Jon liked because, ya know, it's JON. Join your Time Pals as we serve praise, throw copious amounts of…

1
S12 Ep39: Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD 12:25

2M ago12:25

12:25

In this week’s episode of MedNews Week’s Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, sat down with Paul Hanona, MD, to talk about their shared passion for using social media to share accessible information with oncologists and patients alike. Dr Hanona is the chief Hematology …

1
S12 Ep38: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC 44:04

2M ago44:04

44:04

This PER® Spectives™ featured podcast reviews the 22nd Annual Winter Lung Cancer Conference® held in January/February 2025. Multiple successive generations of ALK inhibitors have provided increasing benefits as first-line treatment for the thousands of patients with non-small cell lung cancer (NSCLC) that harbors rearrangements or mutations in the …

1
S12 Ep37: Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD 5:28

2M ago5:28

5:28

In this week’s episode of MedNews Week’s Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, concluded a 3-part series with Vadim Koshkin, MD, an associate professor of medicine in the Division of Hematology and Oncology in the Department of Medicine at the University of California, S…

1
S12 Ep36: Peer Support, Adaptability, and Self-Confidence Are Hallmarks of Successful Oncology Careers: With Liliana Bustamante, MD; and Jessica Stine, MD 23:28

3M ago23:28

23:28

In today’s episode, we sat down with Liliana Bustamante, MD, and Jessica Stine, MD, to discuss their experiences as women in oncology. Dr Bustamante is a medical oncologist and hematologist at Florida Cancer Specialists & Research Institute in Tampa. Dr Stine is the medical director of Gynecologic Oncology at Florida Cancer Specialists & Research I…

1
S12 Ep35: Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD 13:06

3M ago13:06

13:06

In this week's episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, sat down with Vadim Koshkin, MD, an associate professor of medicine in the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco (UCS…

1
S12 Ep34: AR Pathway Inhibition Refines Prostate Cancer Treatment Strategies: With Neal Shore, MD, FACS 8:16

3M ago8:16

8:16

In today’s episode, we had the pleasure of speaking with Neal Shore, MD, FACS, about prostate cancer management and the use of androgen receptor (AR)–directed therapies. Dr Shore is the medical director for the Carolina Urologic Research Center in Myrtle Beach, South Carolina. In our exclusive interview, we sat down with Dr Shore during the 2025 Br…

1
Time Pals Do the Oscars Worst 2006-2010 Edition (Feat. "Hollywood Fringe Legend" Veronica Matthews) 39:23

3M ago39:23

39:23

The Time Pals wrap up their retrospective on the early 2000’s Best Picture winners and should-have-won-ers with special guest “Hollywood Fringe Legend” Veronica Matthews. The fight to correct past Academy mistakes continues! Sould Talladega Nights: The Ballad of Ricky Bobby be acknowledged for its comedic impact or is Jon Powell so woefully wrong? …

1
S12 Ep33: Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD 18:19

3M ago18:19

18:19

In today’s episode, supported by EMD Serono, we had the pleasure of speaking with Chandler Park, MD, about the first-line treatment of patients with bladder cancer. Dr Park is a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky. In our exclusive interview, Dr Park discussed the core regimens in the current frontline bladder …

1
S12 Ep32: ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD 10:30

3M ago10:30

10:30

In this week's episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, sat down with Vadim Koshkin, MD, an associate professor of medicine in the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco (UCS…

1
S12 Ep31: Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD ... 13:54

3M ago13:54

13:54

In today’s episode, we invited experts from across oncology specialties to discuss the long-term effects of the COVID-19 pandemic—the onset of which occurred 5 years ago. Our guests shared how the pandemic's lingering effects continue to shape patient care. We heard from: Ramez N. Eskander, MD, a gynecologic oncologist and assistant professor of ob…

1
Time Pals Do the Oscars Worst 2001-2005 Edition (Feat. "Hollywood Fringe Legend" Veronica Matthews) 1:05:07

3M ago1:05:07

1:05:07

Time Pals begin their peer-reviewed and meticulously researched version of “Marry, Eff, Kill” for the Best Picture Winners and nominees of 2001 through 2005. Join co-hosts Mike Underscore, ShadoSpartan, Jon Powell, and Nickell as they venture through a special two-part episode through the Academy’s most dubious decisions, fixes film history’s wrong…

1
S12 Ep30: Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD 15:16

3M ago15:16

15:16

In today’s episode, OncLive teamed up with CURE to present a discussion with David A. Braun, MD, PhD, about his research on determinants of response to immune checkpoint inhibition (ICI) in patients with renal cell carcinoma (RCC). Dr Braun is an assistant professor of medicine (medical oncology), the Louis Goodman and Alfred Gilman Yale Scholar, a…